Article
Oncology
Sumit Gupta, Rinku Sutradhar, Priscila Pequeno, Johann K. Hitzler, Ning Liu, Paul C. Nathan
Summary: Children with leukemia and Down syndrome (DS) have a higher risk of acute treatment toxicities and late mortality compared to those without DS. DS survivors experienced inferior overall survival compared to non-DS survivors and DS controls. Chronic morbidities associated with DS were not increased compared to DS controls.
Editorial Material
Cell & Tissue Engineering
Malini Gupta, Britta Will
Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.
Article
Medicine, General & Internal
Lindsay M. Morton, Martha S. Linet, Sara J. Schonfeld, Pragati G. Advani, Nicole H. Dalal, Elizabeth C. Sasse
Summary: A study found that the risks of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML) have decreased after chemotherapy and immunotherapy for both common and rare lymphoid neoplasms. The highest risks were observed after precursor leukemia/lymphoma, Burkitt leukemia/lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and mantle cell lymphoma. Recent trends show a significant increase in tMDS/AML risks for CLL/SLL patients, but a decrease for Hodgkin lymphoma and marginal zone lymphoma patients.
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.
Review
Biochemistry & Molecular Biology
Vijendra Singh, Mohammed Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian
Summary: While mechanistic studies have shed light on the molecular mechanisms of AML and led to the development of new targeted therapies, resistance remains a significant issue in AML treatment. The exploration of circRNA in AML biology and therapy resistance shows promise in providing new insights and potential solutions to managing this disease.
Article
Public, Environmental & Occupational Health
Renata Abrahao, Jasmine C. Huynh, David J. Benjamin, Qian W. Li, Lena E. Winestone, Lori Muffly, Theresa H. M. Keegan
Summary: The study found that common late effects among adolescent and young adult survivors of AML include endocrine (26.1%), cardiovascular (18.6%), and respiratory (6.6%). Patients who underwent hematopoietic stem cell transplant (HSCT) or had non-favorable risk AML were more likely to experience various late effects.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami
Summary: Studies have suggested the potential clinical benefits of immuno-oncology therapy against AML, including immune checkpoint inhibitors and bi-/tri-specific antibodies. CAR-T and NK cells have shown effectiveness for relapsed/refractory AML patients, and conventional chemotherapy combined with anti-PD-1/anti-CTLA4 antibodies also demonstrated certain efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Adriana Trabal, Amber Gibson, Jiasen He, David McCall, Michael Roth, Cesar Nunez, Miriam Garcia, Meredith Buzbee, Laurie Toepfer, Aram Bidikian, Naval Daver, Tapan Kadia, Nicholas J. Short, Ghayas C. Issa, Farhad Ravandi, Courtney D. DiNardo, Guillermo Montalban Bravo, Sofia Garces, Andrea Marcogliese, Hana Paek, Zoann Dreyer, Julienne Brackett, Michele Redell, Joanna Yi, Guillermo Garcia-Manero, Marina Konopleva, Alexandra Stevens, Branko Cuglievan
Summary: This article describes the experience of using venetoclax in combination with various therapies for the treatment of pediatric relapsed acute myeloid leukemia (AML) at the Texas Medical Center. The safety and efficacy of this regimen in this population are reported. Evaluation: 8 points
Article
Oncology
Fei Han, Huanhuan Zhao, Jun Lu, Weina Yun, Lingling Yang, Yude Lou, Dan Su, Xin Chen, Shixuan Zhang, Hanwei Jin, Xiang Li, Jie Sun, He Huang, Qishan Wang, Xi Jiang
Summary: This study found that the downregulation of BDH1 gene expression in acute myeloid leukemia (AML) is associated with worse prognosis, and overexpression of BDH1 inhibits the viability and proliferation of AML cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Fenghua Qian, Brooke E. Arner, Kathleen M. Kelly, Charyguly Annageldiyev, Arati Sharma, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Summary: Interleukin-4 (IL-4) plays a therapeutic role in acute myeloid leukemia (AML) by alleviating the severity of the disease. IL-4 enhances the expression of hematopoietic- PGD(2) synthase (H-PGDS) to increase the production of endogenous cyclopentenone prostaglandins (CyPGs), leading to apoptosis of leukemia-initiating cells (LICs).
Review
Oncology
Kristen J. Kurtz, Shannon E. Conneely, Madeleine O'Keefe, Katharina Wohlan, Rachel E. Rau
Summary: Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous hematologic malignancy. Murine models of AML are indispensable research tools to better understand the mechanisms and test novel therapeutic approaches for this disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Muhammed Burak Demircan, Tina M. Schnoeder, Peter C. Mgbecheta, Katrin Schroeder, Frank-D Boehmer, Florian H. Heidel
Summary: Oxidative stress has been found to be associated with cancer initiation and progression. Recent studies have shown the potential therapeutic role of ROS modulation in various cancers, including acute myeloid leukemia (AML). A detailed understanding of the complex machinery regulating ROS in cancer is essential for defining potential therapeutic applications.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Behavioral Sciences
Tyler C. Alexander, Kevin R. Krull
Summary: Survival rates of childhood acute lymphoblastic leukemia have improved greatly due to advanced therapies, but chemotherapy may lead to neurologic and cognitive problems. Long-term cognitive outcomes remain unclear, but further research is needed to understand the effects of chemotherapy on cognitive function.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2021)
Review
Medicine, Research & Experimental
Mengci Hu, Wenzhe Li, Youshan Zhang, Caixia Liang, Jie Tan, Ya Wang
Summary: Venetoclax, a potent BCL-2 inhibitor, has shown significant efficacy in AML treatment in preclinical and clinical trials. However, further research is needed to determine the optimal treatment strategies and identify biomarkers for predicting treatment response.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Engineering, Mechanical
Weigang Sun, Lei Yang, Min Luo
Summary: This paper investigates the dynamics of an acute myeloid leukemia (AML) model with immune response and time delays. The results show that immune response is the best strategy for controlling AML under certain conditions, and a powerful immune response leads to a bistability feature. In addition, time delays induce oscillations around the steady state, making it difficult to eliminate leukemia cells.
NONLINEAR DYNAMICS
(2022)
Letter
Immunology
Mathias Clarysse, Pieter Van Aelst, Tim Vanuytsel, Diethard Monbaliu, Laurens J. Ceulemans, Ann Mertens, Roman Vangoitsenhoven, Bart van der Schueren, Matthias Lannoo, Jacques Pirenne, Ellen Deleus
Article
Oncology
Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Paul C. Nathan, Vijay Ramaswamy
Summary: This study characterized the late effects of childhood medulloblastoma survivors using real-world health services data. The findings reveal significant long-term medical sequelae and increased mortality rates, emphasizing the need for a re-evaluation of current treatment approaches and prioritization of interventions targeting late effects.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
AnnaLynn M. Williams, Jeanne Mandelblatt, Mingjuan Wang, Gregory T. Armstrong, Nickhill Bhakta, Tara M. Brinkman, Wassim Chemaitilly, Matthew J. Ehrhardt, Daniel A. Mulrooney, Brent J. Small, Zhaoming Wang, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson, Kirsten K. Ness, Kevin R. Krull
Summary: This study aimed to compare the accumulation of deficits in survivors of pediatric cancer with community controls and examine associations with host and treatment factors, neurocognition, and mortality. The results showed that pediatric cancer survivors experience clinically significant premature aging, with a DAI score of 0.16 at age 30 corresponding to age 63 in controls (33 years premature aging). Higher DAI scores were associated with increased risk of neurocognitive impairment and death.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Dentistry, Oral Surgery & Medicine
Tushar Patni, Chun-Teh Lee, Yimei Li, Sue Kaste, Liang Zhu, Ryan Sun, Melissa M. Hudson, Kirsten K. Ness, Ana Neumann, Leslie L. Robison
Summary: This study investigated the associations between clinical, socioeconomic, and demographic factors and oral diseases in childhood cancer survivors. The results showed that survivors had a higher prevalence of microdontia, abnormal root development, hypodontia, enamel hypoplasia, xerostomia, severe gingivitis, and missing teeth compared to controls. Cancer treatment, socioeconomic factors, and access to oral health care contributed to the prevalence of dental abnormalities.
Review
Oncology
Madeline R. Horan, Jin-ah Sim, Kevin R. Krull, Kirsten K. Ness, Yutaka Yasui, Leslie L. Robison, Melissa M. Hudson, Justin N. Baker, I-Chan Huang
Summary: Patient-reported outcome measures (PROMs) are useful in assessing the subjective experiences of childhood cancer survivors and can be used to monitor health status and inform medical decision making. This article provides 10 important considerations for clinicians when assessing PROMs for childhood cancer survivors, addressing practical barriers and solutions. An example framework for integrating PROMs into clinical workflow using cutting-edge technologies is also discussed.
Editorial Material
Oncology
Paul C. Nathan, H. Irene Su
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Kohei Hagiwara, Sivaraman Natarajan, Zhaoming Wang, Haseeb Zubair, Heather L. Mulder, Li Dong, Emily M. Plyler, Padma Thimmaiah, Xiaotu Ma, Kristen K. Ness, Zhenghong Li, Daniel A. Mulrooney, Carmen L. Wilson, Yutaka Yasui, Melissa M. Hudson, John Easton, Leslie L. Robison, Jinghui Zhang
Summary: This study provides the first comprehensive investigation of clonal hematopoiesis (CH) in long-term survivors of pediatric cancer. The results show a higher prevalence of CH mutations in survivors compared to community controls. The study also identifies specific genes associated with therapy-related CH in survivors of Hodgkin lymphoma.
Article
Oncology
Qian Dong, Cheng Chen, Nan Song, Na Qin, Noel-Marie Plonski, Emily R. Finch, Kyla Shelton, John Easton, Heather Mulder, Emily Plyer, Geoffrey Neale, Emily Walker, Qian Li, I-Chan Huang, Jinghui Zhang, Hui Wang, Melissa M. Hudson, Leslie L. Robison, Kirsten K. Ness, Zhaoming Wang
Summary: This study conducted an epigenome-wide association analysis on childhood cancer survivors using blood lipid data from the St. Jude lifetime cohort study. The findings revealed that DNA methylation levels of different genes were associated with blood lipid levels, and there were differences between populations of different genetic ancestries. These findings provide insights into the molecular mechanisms of lipid metabolism in childhood cancer survivors.
CLINICAL EPIGENETICS
(2023)
Article
Oncology
Vicky R. Breakey, Rinku Sutradhar, Paul C. Nathan, Serina Patel, Laura Wheaton, Qing Li, Mylene Bassal, Paul Gibson, Jason D. Pole, Uma Athale, Sumit Gupta
Summary: Patient re-engagement with primary care physicians (PCPs) during and after treatment for acute lymphoblastic leukemia (ALL) is low. Involvement of PCPs during treatment can improve post-treatment engagement with PCPs among ALL survivors.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Priya Sayal, Sara Rizakos, Emily Lam, Julie Constantin, Catherine Diskin, Ute Bartels, Julia Orkin, Paul C. Nathan
Summary: This study aimed to explore the experience of parental caregivers caring for medulloblastoma survivors. The study found that parental caregivers face long-term challenges and personal and family impacts. The conclusion of this study is that further improvement is needed in care models and support systems for families with a child who has survived medulloblastoma.
PEDIATRIC BLOOD & CANCER
(2023)
Review
Environmental Sciences
John D. Potter, Collin Brooks, Geoffrey Donovan, Chris Cunningham, Jeroen Douwes
Summary: Humans' encroachment into wild spaces has profound impacts on our relationship with nature, the survival of other species, pollution, and climate change. The benefits of being close to green and blue spaces are discussed, while the hazards of urban grey spaces are highlighted. The biodiversity hypothesis and the role of microbiota are emphasized, along with possible mechanisms of exposure through air, soil, and water. The importance of assessing exposure accurately and the need for implementing policies to restore environmental balance are also emphasized.
SCIENCE OF THE TOTAL ENVIRONMENT
(2023)
Article
Oncology
Daniel C. Bowers, Veena Rajaram, Matthias A. Karajannis, Sharon L. Gardner, Jack Meng-Fen Su, Patricia Baxter, Sonia Partap, Laura J. Klesse
Summary: This phase II clinical trial evaluated the efficacy of everolimus, an mTOR pathway inhibitor, for children with recurrent or progressive posterior fossa-A (PF-A) ependymomas. The study showed that everolimus did not lead to objective tumor responses in these patients. Adverse events were generally mild, with only one case of grade 3 pneumonia.
NEURO-ONCOLOGY ADVANCES
(2023)
Meeting Abstract
Oncology
Tuo Lan, Mei Wang, AnnaLynn M. Williams, Matthew J. Ehrhardt, Emily R. Finch, Jennifer Q. Lanctot, Shu Jiang, Kevin R. Krull, Gregory T. Armstrong, Melissa M. Hudson, Graham A. Colditz, Leslie Robison, Kirsten K. Ness, Yikyung Park
Article
Oncology
Mary Claire Mcglynn, Kassidy Brady, Jessica M. Healey, Vikas R. Dharnidharka, A. Marion Ybarra, Janis Stoll, Stuart Sweet, Robert J. Hayashi
Summary: Survivors of PTLD experience late effects (LE), including late mortality, regardless of chemotherapy exposure. Chemotherapy does not affect survival rate, but is associated with higher incidence of blood and lymphatic toxicity as well as cardiac toxicity, and lower incidence of infections.
PEDIATRIC BLOOD & CANCER
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
V. Ide, D. De Cock, R. Vangoitsenhoven, B. Van Der Schueren, A. Mertens